The Impact of Omega Three Fatty Acids on Vascular Function in HIV

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 129 participants.

Also called NCT01041521

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 129 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01041521
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01041521. Randomized; quadruple masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2014-08 (actual). Results posted on 2020-02-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Impact of Omega Three Fatty Acids on Vascular Function in HIV
Acronym
HOST
Condition
High Triglyceride Level
Condition
HIV Infection
Intervention (Drug)
Lovaza
Lead sponsor
Tufts University (class: other)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct01041521
Content hash
eb33bc3a2480d8750dd1037e9e16beab71d3a3a5d9636b4ed8e88a7c4f1b39a2